1453851-57-4

Basic information

• Product Name: 2(1H)-Pyridinone, 4-[2-(methylthio)-4-pyrimidinyl]-
• Synonyms: 2(1H)-Pyridinone, 4-[2-(methylthio)-4-pyrimidinyl]-;4-[2-(methylsulfanyl)pyrimidin-4-yl]-1,2-dihydropyridin-2-one
• CAS NO: 1453851-57-4
• Molecular Formula: C₁₀H₉N₃OS
• Molecular Weight: 219.26296
• Mol File: 1453851-57-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 504.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• PKA: 11.10±0.10(Predicted)
• CAS DataBase Reference: 2(1H)-Pyridinone, 4-[2-(methylthio)-4-pyrimidinyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Pyridinone, 4-[2-(methylthio)-4-pyrimidinyl]-(1453851-57-4)
• EPA Substance Registry System: 2(1H)-Pyridinone, 4-[2-(methylthio)-4-pyrimidinyl]-(1453851-57-4)

Safety Data

• Hazardous Substances Data: 1453851-57-4(Hazardous Substances Data)

Usage

Structure

A chemical compound containing a pyridinone ring and a pyrimidine ring connected at the 4-position, with a methylthio group attached to the pyrimidine ring.

Derivatives

It is a derivative of both pyridinone and pyrimidine.

Methylthio group

A methyl group (CH3) bonded to a sulfur atom (S), which is attached to the pyrimidine ring.

Uses

It is commonly used as a building block in the synthesis of pharmaceutical compounds and agrochemicals.

Potential applications

It has potential applications in the development of drugs for various diseases and as a component in the production of pesticides and herbicides.

Biological activities

It may exhibit biological activities that could make it useful in medical and agricultural applications.

Upstream product

• 1453851-73-4 4-(2-fluoropyridin-4-yl)-2-(methylthio)pyrimidine 
• 49844-90-8 4-Chloro-2-methylthiopyrimidine 
• 22282-70-8 2-fluoro-4-iodopyridine 
• 401815-98-3 2-fluoropyridin-4-ylboronic acid 
• 959236-97-6 4-bromo-2-methylsulfanylpyrimidine 

Downstream Products

• 1453852-86-2 1-benzhydryl-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453851-79-0 (S)-1-(2-((tert-butyldimethylsilyl)oxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453853-18-3 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chlorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453853-42-3 1-((4-chloro-3-fluorophenyl)(oxazol-5-yl)methyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453853-51-4 tert-butyl 4-((4-chloro-3-fluorophenyl)(4-(2-(methylthio)pyrimidin-4-yl)-2-oxopyridin-1(2H)-yl)methyl)-1H-pyrazole-1-carboxylate 
• 1453854-04-0 (R)-tert-butyl-3-((S)-(4-chloro-3-fluorophenyl)(4-(2-(methylthio)pyrimidin-4-yl)-2-oxopyridin-1(2H)-yl)methyl)pyrrolidine-1-carboxylate 
• 1453854-02-8 (R)-tert-butyl 3-((R)-(4-chloro-3-fluorophenyl)(4-(2-(methylthio)pyrimidin-4-yl)-2-oxopyridin-1(2H)-yl)methyl)pyrrolidine-1-carboxylate 
• 1453852-92-0 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-36-2 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453847-30-7 (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2( 1H)-one 
• 1453852-38-4 1-((S)-2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-((3S,4S)-3-fluorotetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453847-36-3 1-((S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(((3S,4S)-3-fluorotetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2( 1H)-one 
• 1453847-59-0 (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-88-4 1-benzhydryl-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1H)-one 

Relevant articles and documents

Kumada-Corriu Heteroaryl Cross-Coupling for Synthesis of a Pharmaceutical Intermediate: Comparison of Batch Versus Continuous Reaction Modes

Pyridone 1, a key intermediate in the preparation of ERK inhibitor GDC-0994, was synthesized via a cross-coupling/hydrolysis sequence from commercially available starting materials. C-C bond formation was achieved via an efficient palladium catalyzed Kumada-Corriu cross-coupling reaction. However, the 4-pyridylmagnesium halide reagent generated in situ was found to be unstable at the reaction temperature, leading to inconsistent results on scale. In order to address process robustness issues associated with the cross-coupling reaction, we investigated both flow chemistry and a low temperature Kumada-Corriu coupling reaction. Finally, a basic hydrolysis process of 2-fluoropyridine was developed to avoid formation of toxic and corrosive hydrofluoric acid, resulting in a safe and scalable process toward 1.

COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR USE IN TREATMENT OF HYPERPROLIFERATIVE DISEASES

The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

SERINE/THREONINE KINASE INHIBITORS

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.